FDA.reportPublic FDA data

Qelbree 200 MG 24 HR Extended Release Oral Capsule

RxCUI
2536758
RxNorm name
Qelbree 200 MG 24 HR Extended Release Oral Capsule
Display name
Qelbree 200 MG 24 HR Extended Release Oral Capsule
Full name
Qelbree 200 MG 24 HR Extended Release Oral Capsule
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:16

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
aedf408d-0f84-418d-9416-7c39ddb0d29aQelbree 200 MG 24HR Extended Release Oral Capsule [PSN] · 24 HR viloxazine 200 MG Extended Release Oral Capsule [Qelbree] [SBD] · 24 HR Qelbree 200 MG Extended Release Oral Capsule [SY] · Qelbree 200 MG 24 HR Extended Release Oral Capsule [SY]414These highlights do not include all the information needed to use QELBREE ® safely and effectively. See full prescribing information for QELBREE ® . QELBREE ® (viloxazine extended-release capsules), for oral use Initial U.S. Approval: 202120251205